Group 1 - The company has appointed Ernst & Young Hong Kong as the auditing firm for its H-share issuance and listing on the Hong Kong Stock Exchange [1][2][3] - The decision to hire Ernst & Young Hong Kong was made after considering their extensive experience in H-share issuance and their independence and professional capabilities [1][2] - The appointment of the auditing firm requires approval from the company's shareholders' meeting [3] Group 2 - Ernst & Young Hong Kong is registered as a public interest entity auditor under Hong Kong law and has obtained temporary auditing business licenses in mainland China [2] - The firm has a good integrity record, with no significant issues found in the last three years of quality inspections by the Hong Kong Institute of Certified Public Accountants [2] - The company's audit committee reviewed and approved the appointment of Ernst & Young Hong Kong, confirming their qualifications and independence [2][3]

证券代码：301087 证券简称：可孚医疗 公告编号：2025-055 可孚医疗科技股份有限公司 声明人沈楠作为可孚医疗科技股份有限公司第二届董事会独立董事 候选人，已充分了解并同意由提名人可孚医疗科技股份有限公司董事会提名 为可孚医疗科技股份有限公司（以下简称该公司）第二届董事会独立董事候 选人。现公开声明和保证，本人与该公司 之间不存在任何影响本人独立 性的关系，且符合相关法律 、行政法规、部门规章、规范性文件和深圳 证券交易所业 务规则对独立董事候选人任职资格及独立性的要求，具体 声明并承诺如下事项： 一、本人已经通过可孚医疗科技股份有限公司第 二届董事会提名委 员会或者独立董事专门会议资格审查，提名人与本人不存在利害关系或 者其他可能影响独立履职情形的密切关系。 是 □ 否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定 不得担任公司董事的情形。 是 □ 否 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证 券交易所业务规则规定的独立董事任职资格和条件。 是 □ 否 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 是 □ ...

Core Viewpoint - The company plans to issue H shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [1][2]. Group 1: Company Actions - The company convened its second board meeting and supervisory board meeting on August 7, 2025, where it approved the proposal for issuing H shares and listing on the Hong Kong Stock Exchange [1]. - The issuance aims to accelerate the company's global expansion and improve its overseas business capabilities [1]. Group 2: Regulatory Compliance - The issuance and listing are subject to approval from the company's shareholders and must comply with various legal requirements, including those from the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2]. - The company is currently discussing the specifics of the issuance with relevant intermediaries, but details have not yet been finalized [2].

是 □ 否 如否，请详细说明：_______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定 不得担任公司董事的情形。 是 □ 否 证券代码：301087 证券简称：可孚医疗 公告编号：2025-054 可孚医疗科技股份有限公司 提名人可孚医疗科技股份有限公司董事会现就提名沈楠女士为可孚医疗 科技股份有限公司第二届董事会独立董事候选人发表公开声明。被 提名人 已书面同意作为 可孚医疗科技股份有限公司第二届董事会独立董事候选人 （参见该独立董事候选人声明）。本次提 名是在充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情 况后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、 规范性文件和深圳证券交易所业务规则对独立董事候选人任 职资格及独立 性的要求，具体声明并承诺如下事项： 一、被提名人已经通过可孚医疗科技股份有限公司第二届董事会提名委 员会或者独立董事专门会议资格审查，提名人与被提名人不存在利害关系 或者其他可能影响独立履职情形的密切关系。 如否，请详细说明：_________________ ...

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that the adjustments to the 2021 and 2024 restricted stock incentive plans of Kewei Medical Technology Co., Ltd. comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][10][13]. Approval and Authorization - The company held its first board meeting on December 5, 2021, where it approved the draft of the 2021 restricted stock incentive plan and related matters [4][5]. - The company convened its second extraordinary general meeting on December 21, 2021, to approve the 2021 restricted stock incentive plan [6]. - On April 24, 2023, the company approved adjustments to the 2021 restricted stock incentive plan during its board and supervisory board meetings [6][7]. - The company held its second board meeting on March 1, 2024, to approve the draft of the 2024 restricted stock incentive plan [8][9]. Adjustment of Related Matters - The company held its 2024 annual general meeting on May 21, 2024, where it approved a cash dividend distribution of 12 yuan per 10 shares, totaling approximately 244 million yuan [10]. - The adjustments to the grant prices of the restricted stocks for both the 2021 and 2024 incentive plans were made in accordance with the provisions regarding capital increases and dividend distributions [11][12]. Conclusion - The legal opinion asserts that the adjustments to the 2021 and 2024 incentive plans are in compliance with the relevant laws and regulations, ensuring the legality and validity of the actions taken by the company [13].

Group 1 - The Ministry of Industry and Information Technology, along with six other departments, issued a document to promote the innovation and development of the brain-computer interface (BCI) industry, aiming for breakthroughs in key technologies by 2027 [1] - The BCI technology is expected to achieve international advanced levels in electrode, chip, and complete product performance, with applications expanding in industrial manufacturing, healthcare, and consumer life [1] - The global market for BCI medical applications is projected to reach $40 billion by 2030 and $145 billion by 2040 according to McKinsey [1] Group 2 - Local governments are actively supporting the BCI industry with various policies, such as Beijing's action plan targeting commercialization in healthcare, wellness, industrial, and educational fields by 2030 [2] - Companies like Xilinmen and Sanbo Brain Science are entering the BCI field, with Xilinmen launching a smart mattress that integrates brain monitoring technology [2] - Other listed companies are also making strides in material research and AI healthcare, contributing to the BCI industry's supply chain [3] Group 3 - Experts indicate that non-invasive BCI commercialization is progressing rapidly in education and entertainment, while invasive technologies excel in precise control and neuro-rehabilitation [3] - The BCI industry in China benefits from policy support, technological foundation, market space, and application demand, but faces challenges such as technical bottlenecks and ethical concerns [3] - Recommendations include accelerating collaboration on software, hardware, algorithms, and ethics, as well as improving data privacy protection and encouraging leading companies to build public pilot platforms [3]

（文章来源：证券日报） 证券日报网讯 8月8日晚间，可孚医疗发布公告称，公司第二届董事会第十六次会议审议通过了《关于 公司发行H股股票并在香港联合交易所有限公司主板上市的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月8日晚间，可孚医疗发布公告称，公司第二届监事会第十五次会议审议通过了《关于 公司发行H股股票并在香港联合交易所有限公司主板上市的议案》等多项议案。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月8日，可孚医疗发布公告称，公司拟发行境外上市外资 股（H股）并申请在香港联合交易所有限公司主板挂牌上市。公司将充分考虑现有股东利益及境内外资 本市场情况，在股东大会决议有效期内（即经公司股东大会审议通过之日起24个月或自动延长日）或股 东同意延长的其他期限选择适当的时机和发行窗口完成本次发行上市。 ...

Group 1 - The core point of the article is that Kefu Medical (SZ 301087) held its 16th meeting of the second board of directors on August 7, 2025, to discuss the proposal for the re-election of independent directors [1] - For the year 2024, Kefu Medical's revenue composition shows that medical health products account for 95.26%, while other businesses account for 4.74% [1] - As of the report date, Kefu Medical has a market capitalization of 7.8 billion yuan [1]